^{The products will be available in the best pharmacies in Brazil by two weeks. Photo: Prati-Donaduzzi Press.}

Prati-Donaduzzi Pharmaceutical Industry was authorized today (22) by the National Health Regulatory Agency (Anvisa) to market two new concentrations of its product Cannabidiol. The approval published in the Union Official Journal allows two new options on the market, 20 mg/mL and 50 mg/mL, ensuring more accessibility to treatment with 100% nationally produced Cannabidiol.

The new strengths come to the market with lower prices to the population. According to the CEO of the pharmaceutical company, Eder Fernando Maffissoni, the forecast is that the new products will be already available by two weeks in the best pharmacies in Brazil.

 “The research does not stop. Prati-Donaduzzi continues to invest heavily in the development of new products in this segment to continue with its mission of providing health and well-being to millions of Brazilians. We are happy to offer more possibilities of treatment with Cannabidiol for patients, as it shows our commitment as a Brazilian pharmaceutical industry, which has 27 years of history”, assures Maffissoni.

Since last April, the pharmaceutical company has made treatment with Brazilian cannabidiol a reality. The product was launched because ANVISA's RDC 327/2019 created a new category in Brazil, Cannabidiol products. Now, the new strengths are added to the portfolio of the company that already has Cannabidiol Prati-Donaduzzi in 200 mg/ml concentration, presented in oral solution to the consumer.

Availability

All concentrations of Cannabidiol Prati-Donaduzzi are versions of the drug that is in the final stage of phase III clinical study, through a public-private partnership between the pharmaceutical industry and Ribeirão Preto School of Medicine (FMRP) of the University of São Paulo.

For Prati-Donaduzzi's Innovation and Clinical Research manager, Liberato Brum Júnior, placing Cannabidiol-based products on the market is a commitment made to the health of Brazilians. “Prati believes and encourages national innovation. Only in this project, there are more than 6 years of dedication to research. We are the first and only Brazilian pharmaceutical company to allow access to treatment with Cannabidiol produced in our country.”

Liberato reveals that the new product strengths, in addition to expanding the possibilities of treatment, reinforce the reference of the pharmaceutical company in Cannabidiol in Brazil. “We are a pharmaceutical industry certified with Good Manufacturing Practices (GMP), which guarantees us control over the entire production chain, from the used active ingredient to dispensing to the consumer. We use sophisticated techniques and internationally accepted reference standards in each ml of Cannabidiol that will be consumed ”.

Medical Prescription

The new products will expand prescription alternatives for medical professionals, enabling treatments with lower concentrations for different pathologies. As explained by the Director of the Prescription Department in the industry, Edilson Bianqui, there are more options with Prati-Donaduzzi quality assurance. "We deliver pharmaceutical-grade, standardized and safe products, which the physician is assured to prescribe and the patient to use", he concludes.